Keywords: Treatment Response, Cancer, Multi-Center and Multi-Vendor platform, DCE-MRI, Therapy Response, Ktrans
Motivation: Validate Shutter-Speed model (SSM) DCE-MRI as a robust predictor of breast cancer (BC) response to neoadjuvant chemotherapy (NAC) in a multi-center and multi-vendor platform setting.
Goal(s): Compare tumor size, semi-quantitative, and quantitative DCE-MRI for early prediction of NAC response.
Approach: BC patients treated with NAC underwent longitudinal high spatiotemporal resolution DCE-MRI at three sites using a 3T Siemens, GE, or Philips system. Semi-quantitative signal-enhancement-ratio (SER) and quantitative Tofts model (TM) and SSM pharmacokinetic (PK) parameters were derived from DCE time-course data.
Results: PK parameters outperformed size and SER while SSM was superior to TM in early prediction of pathologic response.
Impact: It is feasible to implement quantitative high spatiotemporal resolution SSM DCE-MRI in trials with multi-center and multi-vendor platform settings for robust assessment of BC response to NAC.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords